A diagnostics company and a great long-term growth company. They screen for cancers such as colorectal. It struggled last year, then tanked during Covid. Since then, it's made a big comeback, tripling since the March bottom. They're developing their own Covid test. They just announced positive data for their multi-cancer a liquid biopsy test. If it gets approval, it will widely expand their market. The shares are just shy of last year's old-time high. He expects more upside.
They produce the screening test to detect early colorectal cancer. This is real, and they have much more in the pipeline. That's why the stock is rising.
Your Watchlist
Add stocks to watchlist to monitor them daily and get important alerts.